MedTrace Logo

Abiraterone Post Ketoconazole for Prostate Cancer

NCT01199146 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2018-01-08

Study results available
· View outcomes & findings →

Summary

This is a phase II, open label, single center study to evaluate the efficacy of abiraterone acetate (CB7630) administered to patients with castrate resistant prostate cancer who have experienced disease progression on ketoconazole.

It is hypothesized that abiraterone will be active in patients who have experienced disease progression on ketoconazole

Conditions

Interventions

DRUG

Abiraterone acetate

Abiraterone acetate 1000 mg by mouth per day

Sponsors & Collaborators

Principal Investigators

  • Charles J Ryan, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-10
Primary Completion
2013-01-04
Completion
2016-03-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01199146 on ClinicalTrials.gov